HOTH News and Press, Hoth Therapeutics Inc. From 02/16/23

Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity PR Newswire Strengthens Measures to Safeguard Shareholder Interests through ShareIntel's Investigation and Due Diligence Services for Illegal Short Selling NEW YORK , Feb. 16, 202...

Hoth Therapeutics ( NASDAQ: HOTH ) stock rose ~20% on Wednesday after it reported proof-of-concept data for Alzheimer's disease (AD) drug HT-ALZ in mouse model. The company said the proof-of-concept data was generated using cognitive and behavioral assessments in an...

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ PR Newswire HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK ...

Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy PR Newswire Patient Recruitment Underway NEW YORK , Jan. 25, 202...

Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , Jan. 3, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical ...

Palm Beach, FL – December 30, 2022 – FinancialNewsMedia.com News Commentary – According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. The global rheumatoid arthritis drugs market is ...

Nano-cap biotech Hoth Therapeutics ( NASDAQ: HOTH ) lost ~38% to end a two-day rally in the pre-market Friday after announcing a private placement to sell 2.0M shares of its common stock and warrants to raise $10M in gross proceeds. The capital raise is part of an agreement the co...

Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has...

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy PR Newswire On-track to initiate Phase 2 trial in Q1 2023 NEW YORK , Dec. ...

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 PR Newswire Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused ...